Neu­ro­crine plots 2024 fil­ing for rare dis­ease drug af­ter 'solid' PhI­II win

Neu­ro­crine’s lead neu­roen­docrinol­o­gy pro­gram has passed its first Phase III test, set­ting up a po­ten­tial FDA fil­ing in 2024.

The San Diego biotech saw its shares $NBIX go up al­most 7% to $117.10 Tues­day on the heels of the an­nounce­ment that crinecer­font met pri­ma­ry and key sec­ondary end­points in the Phase III CAH­t­a­lyst tri­al. The tri­al en­rolled 182 adults with clas­sic con­gen­i­tal adren­al hy­per­pla­sia (CAH) due to 21-hy­drox­y­lase de­fi­cien­cy (21-OHD) — mak­ing it the largest ever in­ter­ven­tion­al tri­al con­duct­ed in this rare dis­ease, ac­cord­ing to the prin­ci­pal in­ves­ti­ga­tor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER